Nine Diagnostics Selected for Second Annual Boston Biotech Investor Day
Nine Diagnostics was selected to present at the second annual Boston Biotech Investor Day, an invitation-only Seaport event co-hosted by LabCentral, BioLabs, The Engine, and the Termeer Institute, bringing together 48 early-stage companies with more than 90 leading investors and pharma partners. Nine Diagnostics shared its vision for a biomarker-agnostic, nanosensor-driven platform that uses machine learning to translate complex molecular patterns into clinically actionable insights for oncology. Participation expanded Nine Diagnostics’ network with senior investors and partners shaping the future of precision medicine and AI-enabled diagnostics.
Nine Diagnostics Wins Runner-Up at RESI Boston Longevity Competition
Nine Diagnostics placed second in the Longevity Global Pitch Competition at RESI Boston on September 17, 2025, part of a newly launched longevity and aging track organized by Life Science Nation in partnership with The Engine. The recognition included a one-year Flex-Residency at The Engine and reflects growing interest from the longevity investment community in Nine Diagnostics’ multi-omic nanosensor platform.
The Definitive Reference on Carbon Nanotubes in Biomedicine — Handbook of Carbon Nanomaterials
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-edited a two-volume reference work on carbon nanomaterials in biomedicine, published by World Scientific in 2025 as part of the World Scientific Series on Carbon Nanoscience. The handbook covers the photophysics, surface chemistry, functionalization, and biomedical applications of carbon nanotube-based materials, consolidating the foundational science underlying the Nine Diagnostics platform.
Nine Diagnostics Selected for Inaugural CancerHackerLab Accelerator Cohort
Nine Diagnostics was selected for the inaugural cohort of the CancerHackerLab Accelerator, a cancer-focused innovation program connecting early-stage oncology companies with clinical mentors, biopharma advisors, patient advocates, and a peer community across the cancer innovation ecosystem. Nine Diagnostics joined the cohort as the company was advancing its AI-enabled nanosensor platform for real-time treatment response monitoring in immunotherapy-treated solid tumor patients.
Nine Diagnostics Selected to Participate in The Engine’s Blueprint Program
Nine Diagnostics was selected to participate in The Engine’s Blueprint program, a competitive early-stage cohort for tough tech companies co-founded by MIT, with participation beginning September 13, 2024. The program connected Nine Diagnostics to The Engine’s network of deep science investors, operators, and industry experts as the company defined its regulatory pathway and commercial strategy in its first year.
Nine Diagnostics Selected to Participate in NSF I-Corps Program at MIT
Nine Diagnostics was selected to participate in the NSF I-Corps Program at MIT, a structured customer discovery program administered through the New England Regional Innovation Node at MIT, with participation beginning July 17, 2024. The program provided the Nine Diagnostics team with the framework to rigorously test commercial hypotheses through 100+ customer discovery interviews, directly informing the company’s prioritization of immunotherapy response monitoring in renal cell carcinoma as a lead indication.
Nine Diagnostics Founded to Advance AI-Enabled Nanosensor Diagnostics
Nine Diagnostics was incorporated on March 8, 2024, bringing together Freddy T. Nguyen, MD, PhD, Daniel A. Heller, PhD, and Mijin Kim, PhD to build an AI-enabled multi-omic nanosensor platform for cancer diagnostics. The company was founded to translate peer-reviewed clinical validation studies from the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center into a commercial platform enabling real-time monitoring of disease state and treatment response.
Daniel Heller Featured on NBC New York for AI-Enabled Ovarian Cancer Blood Test Research
Daniel A. Heller, PhD, lead researcher in the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, was featured on NBC New York (WNBC-TV 4) in February 2024 for his work developing an AI-enabled blood test for early ovarian cancer detection, supported by a $900,000 grant from the Ovarian Cancer Research Alliance. Reporter Erica Byfield’s segment highlighted how carbon nanotube nanosensors, lasers, and machine learning can identify cancer signatures in blood.
Mijin Kim Named a 2022 MIT Technology Review Innovator Under 35
Mijin Kim, PhD, a postdoctoral researcher in the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, was named to MIT Technology Review’s 2022 Innovators Under 35 list in the Biotech category, recognized for developing carbon nanotube nanosensor arrays that, combined with machine learning, detect ovarian cancer from blood. The recognition reflected the broad disease-detection potential of the multi-sensor nanosensor architecture developed in the Heller Lab.
Nanosensor Liquid Biopsy Detects Ovarian Cancer with 87% Sensitivity — Nature Biomedical Engineering
Mijin Kim, PhD, and Daniel A. Heller, PhD, at Memorial Sloan Kettering Cancer Center published a landmark study in Nature Biomedical Engineering (March 2022) demonstrating that quantum-defect-modified carbon nanotube nanosensor arrays detect high-grade serous ovarian carcinoma from blood with 87% sensitivity and 98% specificity across 269 patients. The study established a disease-fingerprinting methodology that avoids reliance on predefined biomarkers, forming the core scientific foundation of the Nine Diagnostics platform.